Biomarkers Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

The Biomarkers Market is segmented by Disease (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Renal Disorders, and Other Diseases), Type (Efficacy Biomarker, Safety Biomarker and Validation Biomarker), Mechanism (Genetic, Epigenetic, Proteomic, Lipidomic, and Other Mechanisms), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD billion) for the above-mentioned segments.

Market Snapshot

cancer biomarkers market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 13.76 %
cancer biomarker market forecast

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The biomarker market was valued at approximately USD 41.49 billion in 2020, and it is expected to witness a revenue of USD 90.21 billion in 2026, with a CAGR of 13.76% over the forecast period.

The COVID-19 pandemic led to a lot of disruption in almost every sector. The healthcare sector also faced a similar unprecedented impact in its domain. However, this is not in the case of the biomarker market, as biomarkers are playing a crucial role in the development of therapies for chronic cases, where government and pharmaceutical industries will spend a lot, hindering the market growth.

Moreover, the high prevalence of cancer and cardiac problems increased application, and advancements of biomarkers are the major factors attributed to the market drivers of biomarkers. The spike in cancer cases globally increased the uses with advancement in technology. According to the WCRF (World Cancer Research Fund International), there were 18 million cases around the world. Moreover, the global burden of cancer prevention and cure is of the utmost concern for the governments and pharmaceutical companies.

According to the WHO, cardiovascular diseases (CVD) are taking 17.9 million lives every year, which is equivalent to 31% of all deaths worldwide. CVDs are also at a point where it needs to be addressed immediately. Thus, the future of the biomarker market is positive.

Scope of the Report

A biomarker refers to a biomolecule or gene used to precisely evaluate pharmacologic, pathogenic, and biological procedures in the body. They serve as an early warning in our bodies. It can also be stated as a traceable subsite that is introduced into the body to check/examine the function of the organ. It can be measured and evaluated by using blood, urine, or soft tissues.

The biomarker market is segmented by disease, type, mechanism, and geography. By disease, the market is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, renal disorders, and other diseases. By type, the market is segmented into Efficacy Biomarker, Safety Biomarker and Validation Biomarker. By mechanism, the market is segmented into genetic biomarkers, epigenetic biomarkers, proteomic biomarkers, lipidomic biomarkers, and other mechanisms. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD billion) for the above-mentioned segments.

By Disease
Cardiovascular Disorders
Neurological Disorders
Immunological Disorders
Renal Disorders
Other Diseases
By Type
Efficacy Biomarkers
Prognostic Biomarkers
Pharmacodynamic Biomarkers
Surrogate End Point Markers
Predictive Biomarkers
Safety Biomarkers
Validation Biomarkers
By Mechanism
Genetic Biomarkers
Epigenetic Biomarkers
Proteomic Biomarkers
Lipidomic Biomarkers
Other Mechanisms
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Cancer Biomarkers are Expected to Dominate the Market

Cancer dominates the diseased segment of the biomarker market, as there is a rise in high demand for the detection of cancer cells in the body. The reason attributed to this is the prevalence of cancer globally. Every year, there is a sharp increase in cancer cases. For instance, in 2020, there were 1,806,590 new cases across the world. Government and pharmaceutical companies are spending a lot on the advancement in the therapy, which eventually leads to the growth of the biomarker market globally. There are many types of cancer, and amongst them, breast cancer, lung cancer, and prostate cancer are more prevalent. According to the US National Library of Medicine, there are 1,515 cancer biomarkers that are on clinical trials. The introduction of new cancer biomarkers will increase the market size of biomarkers in the forecast period. Breast cancer and lung cancer dominate the cancer biomarker market, and these cases will increase in the coming years. Thus, the biomarker revenue will also rise up in the forecast period.

cancer biomarker market trends

North America will Dominate the Market in the Forecast Period

North America currently dominates the market for renal biomarkers, and it is expected to continue its stronghold for a few more years. In North America, the United States holds the largest market share. Over the past decade, there has been a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers.

Moreover, almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures. Molecular biomarkers are expected to be identified and validated in drug development and be used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States. According to an American cancer society report, 609,640 deaths occurred due to cancer in this country. There were 234,030 lung cancer cases in America in 2018, and 154,050 deaths occurred due to lung cancer (American Cancer Society data, 2018).

The Canadian biomarker market is the largest, followed by America in North America. The elderly population in Canada anticipates the Canadian market. A large number of people are diagnosed with cancer every year. Lung cancer and prostate cancer are more prevalent in Canada. Thus, the government is spending more in the healthcare domain. Due to these reasons, there will be positive growth in the biomarker market in North America.

cardiac biomarkers market

Competitive Landscape

The biomarker market is moderately competitive. The majority of the market share is possessed by Abbott Laboratories Inc., Johnson & Johnson, Roche Diagnostics, Bio-Rad Laboratories, Epigenomics AG, and Qiagen. The growth of this market majorly depends on the advancement in technology and investment in R&D. Today, most pharmaceutical companies are investing in R&D, and governments are also spending a huge sum of money on the advancement of technology.

In May 2019, QIAGEN received the FDA approval for therascreen RGQ PCR Kit. The therascreenPIK3CA Kit, the first companion diagnostic assay approved to identify breast cancer patients eligible for treatment, is used to identify breast cancer patients who are eligible for treatment.

Recent Developments

  • In January 2021, advancement in biosensors for an inflammatory biomarker of SARS-COV-2. This recent development will help in the increase of market as covid is still and this will help in its detection.
  • In Oct 2020, the recent development of a biomarker sensor was based on electrochemistry and surface plasmon resonance. SPR biosensor is the latest and advanced technology for rapid and sensitive detection of miRNAs.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Prevalence of Life Threatening Diseases

      2. 4.2.2 Increasing Demand for Early Diagnosis of Diseases

      3. 4.2.3 Research Advancements in Finding New Biomarkers

    3. 4.3 Market Restraints

      1. 4.3.1 Issues Related to Regulatory and Reimbursment Systems

      2. 4.3.2 High Cost of Biomarkers

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Disease

      1. 5.1.1 Cancer

      2. 5.1.2 Cardiovascular Disorders

      3. 5.1.3 Neurological Disorders

      4. 5.1.4 Immunological Disorders

      5. 5.1.5 Renal Disorders

      6. 5.1.6 Other Diseases

    2. 5.2 By Type

      1. 5.2.1 Efficacy Biomarkers

        1. Prognostic Biomarkers

        2. Pharmacodynamic Biomarkers

        3. Surrogate End Point Markers

        4. Predictive Biomarkers

      2. 5.2.2 Safety Biomarkers

      3. 5.2.3 Validation Biomarkers

    3. 5.3 By Mechanism

      1. 5.3.1 Genetic Biomarkers

      2. 5.3.2 Epigenetic Biomarkers

      3. 5.3.3 Proteomic Biomarkers

      4. 5.3.4 Lipidomic Biomarkers

      5. 5.3.5 Other Mechanisms

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Quanterix (Aushon Biosystem)

      3. 6.1.3 Bio Rad Laboratories

      4. 6.1.4 Epigenomics AG

      5. 6.1.5 Agilent Technology

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Qiagen NV

      8. 6.1.8 Roche Diagnostics

      9. 6.1.9 Siemens Healthcare GmbH

      10. 6.1.10 Thermo Fisher Scientific Inc

      11. 6.1.11 BioMerieux SA (Astute Medical)

      12. 6.1.12 Zeus scientific

      13. 6.1.13 Myriad genetics

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Biomarkers Market market is studied from 2018 - 2026.

The Global Biomarkers Market is growing at a CAGR of 13.76% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Johnson & Johnson, Roche Diagnostics, Bio-Rad Laboratories, Epigenomics AG, Qiagen are the major companies operating in Global Biomarkers Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!